CUG-BP1 Antibody (1.T.9): sc-56649

CUG-BP1 Antibody (1.T.9) is a mouse monoclonal IgG1 antibody that detects CUG-BP1 in mouse, rat, human, bovine, and porcine samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). CUG-BP1 plays a crucial role in the regulation of RNA splicing and translation, particularly in the context of myotonic dystrophy, a neuromuscular disorder characterized by a (CTG)n repeat expansion in the myotonin protein kinase gene (DMPK). CUG-BP1 is primarily located in the nucleus, where CUG-BP1 binds to CUG repeat sequences, influencing the expression of key regulatory proteins such as p21. Nuclear localization of CUG-BP1 is vital for function, as nuclear positioning allows for precise modulation of mRNA processing and translation in response to cellular signals. Under normal physiological conditions, CUG-BP1 enhances the translation of p21, promoting cell cycle progression and differentiation. However, in myotonic dystrophy, altered binding activity of CUG-BP1 due to expanded CUG repeats leads to a significant reduction in p21 levels, contributing to the disease′s characteristic muscle weakness and atrophy. Anti-CUG-BP1 antibody (1.T.9) is an essential tool for researchers studying the molecular mechanisms underlying myotonic dystrophy and the broader implications of RNA-binding proteins in gene regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CUG-BP1 Antibody (1.T.9) References:

1. CUG-BP1/CELF1 requires UGU-rich sequences for high-affinity binding.  |  Marquis, J., et al. 2006. Biochem J. 400: 291-301. PMID: 16938098
2. GSK3beta-cyclin D3-CUGBP1-eIF2 pathway in aging and in myotonic dystrophy.  |  Jin, J., et al. 2009. Cell Cycle. 8: 2356-9. PMID: 19571675
3. Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1.  |  Vlasova-St Louis, I. and Bohjanen, PR. 2011. Curr Opin Genet Dev. 21: 444-51. PMID: 21497082
4. Suppression of CUGBP1 inhibits growth of hepatocellular carcinoma cells.  |  Liu, Y., et al. 2014. Clin Invest Med. 37: E10-8. PMID: 24502807
5. The Expression of CUGBP1 After Spinal Cord Injury in Rats.  |  Yang, L., et al. 2015. Neurochem Res. 40: 1966-75. PMID: 26283512
6. Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.  |  Timchenko, L. 2019. Int J Mol Sci. 21: PMID: 31877772
7. CELF1 promotes vascular endothelial growth factor degradation resulting in impaired microvasculature in heart failure.  |  Chang, KT., et al. 2021. FASEB J. 35: e21512. PMID: 33811692
8. CELF1 promotes matrix metalloproteinases gene expression at transcriptional level in lens epithelial cells.  |  Xiao, J., et al. 2022. BMC Ophthalmol. 22: 122. PMID: 35287612
9. The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44.  |  David, G., et al. 2022. Biochem Biophys Res Commun. 626: 79-84. PMID: 35973378
10. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy.  |  Lutz, M., et al. 2023. Int J Mol Sci. 24: PMID: 37445828

The preferred CUG-BP1 antibody is CUG-BP1 Antibody (3B1): sc-20003.